ROBOSENSE
19.5.2023 13:01:28 CEST | Business Wire | Press release
RoboSense, a world-leading provider of smart LiDAR sensor systems, today announced it is now connected to the NVIDIA Omniverse ecosystem, using the development platform based on Universal Scene Description (USD) to accelerate the development, testing, and validation of its sensor technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005153/en/
RoboSense Joins NVIDIA Omniverse Ecosystem RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. (Graphic: Business Wire)
RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. With this integration, autonomous vehicle developers can directly access state-of-the-art LiDAR for development and testing. (Video: RoboSense LiDAR Model in NVIDIA DRIVE Sim)
DRIVE Sim is a reference application built on NVIDIA Omniverse, the connecting fabric between software ecosystems. It combines NVIDIA’s core technologies to deliver digital twin environments for developing and testing autonomous driving systems. With DRIVE Sim, developers can perform diverse and repeatable testing scenarios at a large scale, accelerating development and reducing cost.
As part of the Omniverse ecosystem, RoboSense will use the simulation platform to test and validate its new LiDAR systems - as well as provide ADAS developers access to highly accurate simulation models.
RoboSense's M-Series LiDAR is the world's first second-generation smart solid-state LiDAR to achieve mass production for automotive applications. It is currently the LiDAR with the most designated partnerships worldwide and has been implemented in a variety of vehicle models including the GAC Aion LX Plus, GAC Aion Hyper GT, SAIC IM LS7, SAIC IM L7, Lotus Eletre, XPeng G9, XPeng P7i, Great Wall WEY Mocha DHT-PHEV, Great Wall Motor WEY DHT-PHEV, and Chery Exeed STERRA ES, STERRA ET.
The M-Series LiDAR features a revolutionary two-dimensional MEMS scanning architecture, with unique “GAZE” function that can dynamically switch scanning modes and change scanning patterns based on the scenario, improving vehicle perception in complex environments. Based on RoboSense's leading patented technology, the M-Series LiDAR delivers point-cloud with outstanding quality, helping to address corner cases in autonomous driving perception.
By joining the NVIDIA Omniverse ecosystem, RoboSense enables developers to create complex road environments with high physical accuracy using its LiDAR model on the DRIVE Sim platform. The M series LiDAR model offers the flexibility to simulate its performance in beam control, custom scan patterns, and resolutions, which can then be used to generate synthetic datasets for training and validation of autonomous driving solutions.
Mark Qiu, co-founder and executive president of RoboSense, said, “The global automotive industry is undergoing a massive transformation, with ADAS and LiDAR markets continuing to gain traction. Leveraging the NVIDIA Omniverse ecosystem, RoboSense LiDAR technology and industry experience can be applied in a wider field, providing strong support for the development and verification of autonomous vehicles. RoboSense will work with NVIDIA to fully leverage the advantages of LiDAR technology, continuously improve the perception capabilities of autonomous vehicles, and achieve more efficient, safer, and smarter autonomous driving applications. We are committed to promoting the development of the global automotive and autonomous driving industries.”
Zvi Greenstein, a general manager at NVIDIA, said, “NVIDIA Omniverse is an open platform that includes leading LiDAR models from manufacturers worldwide. RoboSense's outstanding technical strength and customer base help strengthen our ecosystem and will accelerate the development and validation of autonomous vehicles while bringing more flexibility to developers.”
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom